BiPar Sciences biparsciences.com


Public list: Pharma Startups (4734) Cancer Therapeutics (1145)

BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including therapy-resistant and difficult-to-treat cancers.

BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including therapy-resistant and difficult-to-treat cancers.

Company (Acquired)

Phone: 650-635-6050

Fax:

1000 Marina Boulevard
Suite 550
Brisbane, 94005
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
BiPar Sciences $67.5M Apr 15, 2009
OncoMed Pharmaceuticals $376.2M Dec 6, 2018
Activate Immunotherapy $0M Aug 15, 2016
See all 17 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related BiPar Sciences Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 10 investors

Board Members

Competitors

Company Status Description Investors
See all 17 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Treatment of cancer Sep 05, 2007 Mar 27, 2012 Patent
Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds Sep 05, 2007 Aug 09, 2011 Patent
Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents Nov 11, 2008 Jun 08, 2010 Patent
Drug design for tubulin inhibitors, compositions, and methods of treatment thereof Sep 05, 2007 May 26, 2009 Patent
Treatment of cancer Nov 29, 2012 Application